Sarepta Therapeutics (SRPT) Shares Outstanding (Weighted Average) (2010 - 2026)

Sarepta Therapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $105.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 7.83% year-over-year to $105.0 million; the trailing twelve-month figure through Mar 2026 stood at $105.0 million (up 7.83% YoY), and the FY2025 full-year result was $100.1 million, up 5.31% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $105.0 million, up from $100.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $105.0 million in Q1 2026, with the low at $87253.0 in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $88.1 million, with a median of $94.0 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) surged 109649.67% in 2022 and advanced 1.09% in 2023.
• Tracing SRPT's Shares Outstanding (Weighted Average) over 5 years: stood at $87.6 million in 2022, then gained by 5.53% to $92.4 million in 2023, then increased by 2.9% to $95.1 million in 2024, then advanced by 5.31% to $100.1 million in 2025, then grew by 4.86% to $105.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $105.0 million (Q1 2026), $100.1 million (Q4 2025), and $98.5 million (Q3 2025), per Business Quant data.

Peer Comparison